JP2011527330A - スニチニブリンゴ酸塩の結晶形の調製方法 - Google Patents

スニチニブリンゴ酸塩の結晶形の調製方法 Download PDF

Info

Publication number
JP2011527330A
JP2011527330A JP2011517242A JP2011517242A JP2011527330A JP 2011527330 A JP2011527330 A JP 2011527330A JP 2011517242 A JP2011517242 A JP 2011517242A JP 2011517242 A JP2011517242 A JP 2011517242A JP 2011527330 A JP2011527330 A JP 2011527330A
Authority
JP
Japan
Prior art keywords
sunitinib
malic acid
dissolved
mixture
sunitinib malate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527330A5 (enExample
Inventor
ガイトンデ，アブヘイ
ゴレ，ビナーヤク
チョウダーリ，バラティ
フブリカール，マヘシ
バンソデ，プラカシュ
ファドタレ，スナンダ
Original Assignee
ジェネリクス・（ユーケー）・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・（ユーケー）・リミテッド filed Critical ジェネリクス・（ユーケー）・リミテッド
Publication of JP2011527330A publication Critical patent/JP2011527330A/ja
Publication of JP2011527330A5 publication Critical patent/JP2011527330A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011517242A 2008-07-10 2009-07-09 スニチニブリンゴ酸塩の結晶形の調製方法 Pending JP2011527330A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1193KO2008 2008-07-10
IN1193/KOL/2008 2008-07-10
PCT/GB2009/050818 WO2010004339A1 (en) 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate

Publications (2)

Publication Number Publication Date
JP2011527330A true JP2011527330A (ja) 2011-10-27
JP2011527330A5 JP2011527330A5 (enExample) 2012-08-23

Family

ID=41100787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517242A Pending JP2011527330A (ja) 2008-07-10 2009-07-09 スニチニブリンゴ酸塩の結晶形の調製方法

Country Status (7)

Country Link
US (1) US20110257237A1 (enExample)
EP (1) EP2297138A1 (enExample)
JP (1) JP2011527330A (enExample)
CN (1) CN102203085A (enExample)
AU (1) AU2009269768A1 (enExample)
CA (1) CA2730079A1 (enExample)
WO (1) WO2010004339A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
WO2011058521A2 (en) * 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
EP2528913A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2013140232A1 (en) * 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523340A (ja) * 2000-02-15 2003-08-05 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
JP2005503386A (ja) * 2001-08-15 2005-02-03 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Ｎ−［２−（ジエチルアミノ）エチル］−５−［（５−フルオロ−１，２−ジヒドロ−２−オキソ−３ｈ−インドール−３−イリデン）メチル］−２，４−ジメチル−１ｈ−ピロール−３−カルボキシアミドのリンゴ酸塩を含む結晶、その製法およびその組成物
JP2006518756A (ja) * 2003-02-24 2006-08-17 スージェン・インコーポレーテッド インドリノン化合物による過度の骨溶解の治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1758914A (zh) * 2003-02-24 2006-04-12 苏根公司 用吲哚啉酮化合物治疗过度骨质溶解
EP2220072A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523340A (ja) * 2000-02-15 2003-08-05 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
JP2005503386A (ja) * 2001-08-15 2005-02-03 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Ｎ−［２−（ジエチルアミノ）エチル］−５−［（５−フルオロ−１，２−ジヒドロ−２−オキソ−３ｈ−インドール−３−イリデン）メチル］−２，４−ジメチル−１ｈ−ピロール−３−カルボキシアミドのリンゴ酸塩を含む結晶、その製法およびその組成物
JP2006518756A (ja) * 2003-02-24 2006-08-17 スージェン・インコーポレーテッド インドリノン化合物による過度の骨溶解の治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
実験化学講座（続）２ 分離と精製, JPN6012022299, 25 January 1967 (1967-01-25), JP, pages 159 - 178, ISSN: 0002696592 *
新・薬剤学総論（改訂第３版）, vol. 株式会社南江堂, JPN6012025458, 10 April 1987 (1987-04-10), JP, pages 111, ISSN: 0002696591 *
新製剤学, JPN6012022297, 25 April 1984 (1984-04-25), JP, pages 102 - 103, ISSN: 0002696590 *
調剤学−基礎と応用−, JPN6012022295, 20 September 1977 (1977-09-20), JP, pages 142 - 145, ISSN: 0002696589 *

Also Published As

Publication number Publication date
WO2010004339A1 (en) 2010-01-14
CA2730079A1 (en) 2010-01-14
CN102203085A (zh) 2011-09-28
US20110257237A1 (en) 2011-10-20
EP2297138A1 (en) 2011-03-23
AU2009269768A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
JP2011527330A (ja) スニチニブリンゴ酸塩の結晶形の調製方法
JP2011512396A (ja) 新規な多形およびその調製方法
JP6211072B2 (ja) ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
JP2019052152A (ja) トレプロスチニルの塩
JP5373996B2 (ja) サクサグリプチン中間体、サクサグリプチン多形及びそれらの調製方法
JP6501773B2 (ja) 結晶形態のダサチニブの塩
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
WO2014194795A1 (zh) 吲哚酮化合物或其衍生物及其用途
WO2022123334A1 (en) "pharmaceutical polymorphs of molnupiravir"
US20120029046A1 (en) Crystalline form of sunitinib and processes for its preparation
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
JP2011526615A (ja) ３−ピロール置換２−インドリノン誘導体の調製
US20110263670A1 (en) Novel polymorphs of sunitinib and processes for their preparation
JPH08510477A (ja) 新規なｎ−ベンゾイルメチル−ピペリジン類
JP6072908B2 (ja) 重水素化ω―ジメチル尿素又はその塩の多形物
CN118324750A (zh) 三嗪衍生物富马酸共晶的制备方法
TW202411221A (zh) 一種三嗪二酮類衍生物的晶型及製備方法
TW202342138A (zh) Ａｔｘ抑制劑或其鹽的結晶形式及其制備方法與應用
CN119613386A (zh) 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
KR0179080B1 (ko) 2-(4-아미노벤조일아미노)벤즈아미드유도체와 그 제조방법 및 이를 함유하는 소염진통제
JP2004035486A (ja) パラフェニレンジアミン誘導体
JP2004035484A (ja) シクロヘキサンジアミン誘導体
WO2006082598A2 (en) Novel crystalline forms of rizatriptan benzoate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140422